Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lale Tokgozoglu

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Circulation|May 25, 2026
Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV TrialVictorien Monguillon, Nicholas A Marston, Erin A Bohula, et al.
Atherosclerosis|February 7, 2018
A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)Meral Kayikcioglu, Lale Tokgozoglu, Mehmet Yilmaz, et al.
European Heart Journal|December 11, 2025
C-reactive protein and cardiovascular risk in the general populationBerkan Kurt, Martin Reugels, Kai M Schneider, et al.
JAMA|March 28, 2026
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV TrialNicholas A Marston, Erin A Bohula, Ajay K Bhatia, et al.
Journal of Clinical Lipidology|April 1, 2019
Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry)Meral Kayikcioglu, Ozlem Kuman-Tunçel, Sebnem Pirildar, et al.
Revista Espanola De Cardiologia (English Ed.)|May 7, 2022
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)Frank L J Visseren, François Mach, Yvo M Smulders, et al.
European Heart Journal|August 30, 2021
2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceFrank L J Visseren, François Mach, Yvo M Smulders, et al.
European Journal of Preventive Cardiology|September 24, 2021
2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceFrank L J Visseren, François Mach, Yvo M Smulders, et al.
Giornale Italiano Di Cardiologia (2006)|June 16, 2022
[2021 ESC Guidelines on cardiovascular disease prevention in clinical practice]Frank L J Visseren, François Mach, Yvo M Smulders, et al.
Atherosclerosis. Supplements|May 21, 2014
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practiceNaveed A Sattar, Henry Ginsberg, Kausik Ray, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Circulation|May 25, 2026
Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV TrialVictorien Monguillon, Nicholas A Marston, Erin A Bohula, et al.
Atherosclerosis|February 7, 2018
A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)Meral Kayikcioglu, Lale Tokgozoglu, Mehmet Yilmaz, et al.
European Heart Journal|December 11, 2025
C-reactive protein and cardiovascular risk in the general populationBerkan Kurt, Martin Reugels, Kai M Schneider, et al.
JAMA|March 28, 2026
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV TrialNicholas A Marston, Erin A Bohula, Ajay K Bhatia, et al.
Journal of Clinical Lipidology|April 1, 2019
Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry)Meral Kayikcioglu, Ozlem Kuman-Tunçel, Sebnem Pirildar, et al.
Revista Espanola De Cardiologia (English Ed.)|May 7, 2022
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)Frank L J Visseren, François Mach, Yvo M Smulders, et al.
European Heart Journal|August 30, 2021
2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceFrank L J Visseren, François Mach, Yvo M Smulders, et al.
European Journal of Preventive Cardiology|September 24, 2021
2021 ESC Guidelines on cardiovascular disease prevention in clinical practiceFrank L J Visseren, François Mach, Yvo M Smulders, et al.
Giornale Italiano Di Cardiologia (2006)|June 16, 2022
[2021 ESC Guidelines on cardiovascular disease prevention in clinical practice]Frank L J Visseren, François Mach, Yvo M Smulders, et al.
Atherosclerosis. Supplements|May 21, 2014
The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practiceNaveed A Sattar, Henry Ginsberg, Kausik Ray, et al.
Pageof 15